UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

Clinical cancer research, 2008-07, Vol.14 (14), p.4556-4563

2008

Volltextzugriff (PDF)

The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor

Breast cancer research and treatment, 2011-08, Vol.128 (3), p.667-677

2011

Volltextzugriff (PDF)

The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma

Molecular cancer therapeutics, 2005-05, Vol.4 (5), p.824-834

2005

Volltextzugriff (PDF)

The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 Mice

Clinical cancer research, 2007-10, Vol.13 (20), p.6224-6231

2007

Volltextzugriff (PDF)

Suppression of Mammary Tumorigenesis in Transgenic Mice by the RXR-selective Retinoid, LGD1069

Cancer epidemiology, biomarkers & prevention, 2002-05, Vol.11 (5), p.467-474

2002

Volltextzugriff (PDF)

A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer

Clinical cancer research, 2004-12, Vol.10 (24), p.8656-8664

2004

Volltextzugriff (PDF)

Synthesis and Characterization of Nonsteroidal Glucocorticoid Receptor Modulators for Multiple Myeloma

Journal of medicinal chemistry, 2007-09, Vol.50 (19), p.4699-4709

2007

Volltextzugriff (PDF)

Prevention and Treatment of Experimental Breast Cancer with the Combination of a New Selective Estrogen Receptor Modulator, Arzoxifene, and a New Rexinoid, LG 100268

Clinical cancer research, 2002-10, Vol.8 (10), p.3270-3275

2002

Volltextzugriff (PDF)

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure

JNCI : Journal of the National Cancer Institute, 1999-12, Vol.91 (24), p.2118-2123

1999

Volltextzugriff (PDF)

Induction of proto-oncogene JUN /AP-1 by serum and TPA

Nature (London), 1988-08, Vol.334 (6183), p.629-631

1988

Volltextzugriff (PDF)

Identification of a nuclear receptor that is activated by farnesol metabolites

Cell, 1995-06, Vol.81 (5), p.687-693

1995

Volltextzugriff (PDF)

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice

Cancer research (Chicago, Ill.), 2002-11, Vol.62 (22), p.6376-6380

2002

Volltextzugriff (PDF)

Responsiveness to the Retinoic Acid Receptor-selective Retinoid LGD1550 Correlates with Abrogation of Transforming Growth Factor α/Epidermal Growth Factor Receptor Autocrine Signaling in Head and Neck Squamous Carcinoma Cells

Clinical cancer research, 2003-09, Vol.9 (11), p.4205-4213

2003

Volltextzugriff (PDF)

G0S2 is an all-trans-retinoic acid target gene

International journal of oncology, 2008-08, Vol.33 (2), p.397-404

2008

Volltextzugriff (PDF)

Rexinoid-induced Expression of IGFBP-6 Requires RARβ-dependent Permissive Cooperation of Retinoid Receptors and AP-1

The Journal of biological chemistry, 2009-01, Vol.284 (1), p.345-353

2009

Volltextzugriff (PDF)

A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer

The Prostate, 2006-02, Vol.66 (3), p.305-316

2006

Volltextzugriff (PDF)

Repression of exogenous gene expression by the retinoic acid target gene G0S2

International journal of oncology, 2013-05, Vol.42 (5), p.1743-1753

2013

Volltextzugriff (PDF)

Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells

Cancer research (Chicago, Ill.), 1997-11, Vol.57 (21), p.4931-4939

1997

Volltextzugriff (PDF)

Beyond tamoxifen : The retinoid X receptor-selective ligand LGD1069 (targretin) causes complete regression of mammary carcinoma

Cancer research (Chicago, Ill.), 1998-02, Vol.58 (3), p.479-484

1998

Volltextzugriff (PDF)

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

Molecular cancer therapeutics, 2008-05, Vol.7 (5), p.1251-1257

2008

Volltextzugriff (PDF)

The retinoid X receptor-selective retinoid, LGD1069, down- regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk : Implications for molecular-based chemoprevention

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (8), p.3462-3469

2005

Volltextzugriff (PDF)

Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays

Cancer research (Chicago, Ill.), 2006-12, Vol.66 (24), p.12009-12018

2006

Volltextzugriff (PDF)

Chemoprevention of mammary carcinoma by LGD1069 (Targretin) : An RXR-selective ligand

Cancer research (Chicago, Ill.), 1996-12, Vol.56 (24), p.5566-5570

1996

Volltextzugriff (PDF)

Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade

Breast cancer research and treatment, 2006-03, Vol.96 (2), p.147-157

2006

Volltextzugriff (PDF)

Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

Breast cancer research and treatment, 2004-11, Vol.88 (2), p.141-148

2004

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(67)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(45)
Biological And Medical Sciences
(40)
Animals
(36)
Humans
(34)
Medical Sciences
(32)
Oncology
(31)
Mice
(23)
Female
(22)
Antineoplastic Agents
(21)
Pharmacology. Drug Treatments
(21)
Tetrahydronaphthalenes - Pharmacology
(18)
Retinoid X Receptors
(16)
Tumors
(14)
Cell Division - Drug Effects
(13)
Anticarcinogenic Agents - Pharmacology
(12)
Receptors, Retinoic Acid - Metabolism
(12)
Transcription Factors - Metabolism
(11)
Tumor Cells, Cultured
(11)
Antineoplastic Agents - Pharmacology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor

The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma

The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 Mice

Suppression of Mammary Tumorigenesis in Transgenic Mice by the RXR-selective Retinoid, LGD1069

A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non–Small Cell Lung Cancer

Synthesis and Characterization of Nonsteroidal Glucocorticoid Receptor Modulators for Multiple Myeloma

Prevention and Treatment of Experimental Breast Cancer with the Combination of a New Selective Estrogen Receptor Modulator, Arzoxifene, and a New Rexinoid, LG 100268

Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure

Induction of proto-oncogene JUN /AP-1 by serum and TPA

Identification of a nuclear receptor that is activated by farnesol metabolites

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice

Responsiveness to the Retinoic Acid Receptor-selective Retinoid LGD1550 Correlates with Abrogation of Transforming Growth Factor α/Epidermal Growth Factor Receptor Autocrine Signaling in Head and Neck Squamous Carcinoma Cells

G0S2 is an all-trans-retinoic acid target gene

Rexinoid-induced Expression of IGFBP-6 Requires RARβ-dependent Permissive Cooperation of Retinoid Receptors and AP-1

A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer

Repression of exogenous gene expression by the retinoic acid target gene G0S2

Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells

Beyond tamoxifen : The retinoid X receptor-selective ligand LGD1069 (targretin) causes complete regression of mammary carcinoma

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

The retinoid X receptor-selective retinoid, LGD1069, down- regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk : Implications for molecular-based chemoprevention

Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays

Chemoprevention of mammary carcinoma by LGD1069 (Targretin) : An RXR-selective ligand

Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade

Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

Suchergebnisse filtern